pre-IPO PHARMA

COMPANY OVERVIEW

AT KERNAL BIO, we aim to harness the power of our mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease — while eliminating as many common side effects as possible. Our unique inside-out approach attacks diseases like cancer at the cellular level. Our proprietary mRNA technology is engineered to move in stealth, undetected by the immune system, and encrypted to home in on cancer cells, making it distinctively onco-selective. Thus, we maximize the potential to improve patient outcomes compared to existing synthetic mRNA. Beyond our work in cancer therapeutics, we also license a portion of our technology to global pharma and biotech companies for non-oncology applications, which helps further and fund our internal development programs.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.kernalbio.com/


    CAREER WEBSITE

    https://www.kernalbio.com/careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jul 7, 2022

    Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology


    Nov 9, 2021

    Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference


    Jul 22, 2021

    Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product


    For More Press Releases


    Google Analytics Alternative